The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.

Long-term culture of MCF-7 wild-type (wt) cells in steroid-depleted medium (LTED) results in hypersensitivity to oestradiol (E2) coinciding with elevated levels of ERalpha and enhanced growth factor signalling. In this study, we aimed to compare the effects of the pure anti-oestrogen ICI 182,780 (ICI) with the competitive anti-oestrogen tamoxifen (TAM) on oestrogen and IGF signalling in these cells. Wt MCF-7 and LTED cells were treated with a log 7 concentration range of E2, TAM or ICI. Effects on cell growth, ERalpha transactivation, expression of ERalpha, ERbeta and components of the IGF pathway were measured with and without insulin. In the presence of insulin, growth of LTED cells was refractory to TAM but inhibited by ICI and E2. In the absence of insulin, LTED cells showed persistent hypersensitivity to E2, and remained inhibited by ICI but were largely unaffected by TAM. ICI but not TAM inhibited ER-mediated gene transcription and treatment with ICI resulted in a dose-dependent reduction in ERalpha levels whilst having no effect on ERbeta expression. IGF-I receptor and insulin receptor substrate 2 levels were increased in LTED versus the Wt MCF-7 cells, and ICI but not TAM reduced their expression in a dose-dependent fashion. Thus IGF signalling as well as ERalpha expression and function are enhanced during LTED. While the resultant cells are resistant to TAM, ICI down-regulates ERalpha, reducing IGF signalling and cell growth. These results support the use of ICI in women with ER-positive breast cancer who have relapsed on an aromatase inhibitor.

[1]  M. Karin,et al.  AP-1 in cell proliferation and survival , 2001, Oncogene.

[2]  F. May,et al.  Paradoxical effects of overexpression of the type I insulin-like growth factor (IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol. , 1996, Endocrinology.

[3]  D. Heitjan,et al.  Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. , 1995, The Journal of clinical endocrinology and metabolism.

[4]  H. Huynh,et al.  Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  P. Lønning,et al.  Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Powles,et al.  Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. , 1987, Cancer research.

[7]  C. Osborne,et al.  Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. , 2001, Cancer research.

[8]  Hong Liu,et al.  Apoptotic Action of 17β-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo , 2003 .

[9]  Anthony Howell,et al.  Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma , 1998, Cancer.

[10]  E. Surmacz,et al.  Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. , 1997, Cancer research.

[11]  D. Yee,et al.  Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells* , 1998, The Journal of Biological Chemistry.

[12]  R. Kumar,et al.  Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. , 1998, Endocrinology.

[13]  B. Katzenellenbogen,et al.  The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. , 1999, Molecular endocrinology.

[14]  M. Pollak,et al.  Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells (*) , 1996, The Journal of Biological Chemistry.

[15]  Mitch Dowsett,et al.  Aromatase inhibitors for breast cancer: lessons from the laboratory , 2003, Nature Reviews Cancer.

[16]  Christopher J. Barnes,et al.  The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Darbre,et al.  Insulin-like Growth Factor Receptor Levels Are Regulated by Cell Density and by Long Term Estrogen Deprivation in MCF7 Human Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[18]  M. Dowsett,et al.  Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  Hong Liu,et al.  Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. , 2003, Journal of the National Cancer Institute.

[20]  Ji-ping Wang,et al.  Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  S. Andò,et al.  Role of IRS-1 signaling in insulin-induced modulation of estrogen receptors in breast cancer cells. , 1998, Biochemical and biophysical research communications.

[22]  R. Blamey,et al.  Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. , 1996, European journal of cancer.

[23]  D. Márquez,et al.  Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells , 2001, Oncogene.

[24]  E. Surmacz,et al.  Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  F. May,et al.  Insulin Receptor Substrate-1 Expression Is Regulated by Estrogen in the MCF-7 Human Breast Cancer Cell Line* , 2000, The Journal of Biological Chemistry.

[27]  V. Jordan,et al.  Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  C. Sonnenschein,et al.  Identification and characterization of membrane estrogen receptor from MCF7 estrogen-target cells , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  P. Dombernowsky,et al.  Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[31]  S. Hilsenbeck,et al.  Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. , 2005, Molecular endocrinology.

[32]  M. Kerin,et al.  Advances in Brief Increased Expression of Estrogen Receptor b mRNA in Tamoxifen-resistant Breast Cancer Patients 1 , 1999 .

[33]  M. van Eickels,et al.  Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway* , 2000, The Journal of Biological Chemistry.

[34]  S. Hilsenbeck,et al.  Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. , 1999, Molecular endocrinology.

[35]  M. Johnson,et al.  Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. , 1990, The Journal of biological chemistry.

[36]  R. McPherson,et al.  Linkage of Rapid Estrogen Action to MAPK Activation by ER-Shc Association and Shc Pathway Activation , 2001 .

[37]  J. Robertson,et al.  Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. , 1999, Endocrine-related cancer.

[38]  R. McPherson,et al.  Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. , 2001, Journal of the National Cancer Institute.

[39]  H. Huynh,et al.  Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Andò,et al.  Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells , 1999, International journal of cancer.

[42]  Rakesh Kumar,et al.  Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cells in Vivo1. , 2000, Endocrinology.

[43]  A. Buzdar.  Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. , 2003, The oncologist.

[44]  K. Takano,et al.  Estrogenic impurities in labware , 2001, Nature Biotechnology.

[45]  M. Dowsett,et al.  Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation* , 2003, Journal of Biological Chemistry.

[46]  P. Darbre,et al.  Effect of estradiol on human breast cancer cells in culture. , 1983, Cancer research.

[47]  A. Howell,et al.  Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  G. Mor,et al.  Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER+ breast cancer cells , 2005, Apoptosis.

[49]  L. Murphy,et al.  Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. , 1998, Cancer research.

[50]  A. Wakeling,et al.  ICI 182,780, a new antioestrogen with clinical potential , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[51]  P. Smith,et al.  Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. , 1988, The Journal of biological chemistry.

[52]  R. McPherson,et al.  Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17β-Estradiol , 2001 .